Related references
Note: Only part of the references are listed.A Novel Role of Cyclic Nucleotide Phosphodiesterase 10A in Pathological Cardiac Remodeling and Dysfunction
Si Chen et al.
CIRCULATION (2020)
Cardiac Overexpression of PDE4B Blunts β-Adrenergic Response and Maladaptive Remodeling in Heart Failure
Sarah Karam et al.
CIRCULATION (2020)
A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD
Dave Singh et al.
RESPIRATORY RESEARCH (2020)
Phosphodiesterase type 3A (PDE3A), but not type 3B (PDE3B), contributes to the adverse cardiac remodeling induced by pressure overload
Nazari Polidovitch et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2019)
Imaging cAMP nanodomains in the heart
Ying-Chi Chao et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2019)
Milrinone Dosing and a Culture of Caution in Clinical Practice
Luke Yong Zheng Chong et al.
CARDIOLOGY IN REVIEW (2018)
Multiprotein Complex With TRPC (Transient Receptor Potential-Canonical) Channel, PDE1C (Phosphodiesterase 1C), and A2R (Adenosine A2 Receptor) Plays a Critical Role in Regulating Cardiomyocyte cAMP and Survival
Yishuai Zhang et al.
CIRCULATION (2018)
Acute Enhancement of Cardiac Function by Phosphodiesterase Type 1 Inhibition: Translational Study in the Dog and Rabbit
Toru Hashimoto et al.
CIRCULATION (2018)
Basal Spontaneous Firing of Rabbit Sinoatrial Node Cells Is Regulated by Dual Activation of PDEs (Phosphodiesterases) 3 and 4
Tatiana M. Vinogradova et al.
CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY (2018)
An update on vinpocetine: New discoveries and clinical implications
Yi-shuai Zhang et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2018)
Phosphodiesterase 2 inhibition preferentially promotes NO/guanylyl cyclase/cGMP signaling to reverse the development of heart failure
Reshma S. Baliga et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Roles of PDE1 in Pathological Cardiac Remodeling and Dysfunction
Si Chen et al.
JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE (2018)
Phosphodiesterase 2 Protects Against Catecholamine-Induced Arrhythmia and Preserves Contractile Function After Myocardial Infarction
Christiane Vettel et al.
CIRCULATION RESEARCH (2017)
Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health-related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension
Licette C. Y. Liu et al.
EUROPEAN JOURNAL OF HEART FAILURE (2017)
PDE2A2 regulates mitochondria morphology and apoptotic cell death via local modulation of cAMP/PKA signalling
Stefania Monterisi et al.
ELIFE (2017)
Vinpocetine Attenuates Pathological Cardiac Remodeling by Inhibiting Cardiac Hypertrophy and Fibrosis
Mei-ping Wu et al.
CARDIOVASCULAR DRUGS AND THERAPY (2017)
Calmodulin kinase II inhibition limits the pro-arrhythmic Ca2+ waves induced by cAMP-phosphodiesterase inhibitors
Pierre Bobin et al.
CARDIOVASCULAR RESEARCH (2016)
A novel thermoregulatory role for PDE10A in mouse and human adipocytes
Mohammed K. Hankir et al.
EMBO MOLECULAR MEDICINE (2016)
MicroRNA in Control of Gene Expression: An Overview of Nuclear Functions
Caterina Catalanotto et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Novel approaches to targeting PDE3 in cardiovascular disease
Matthew Movsesian
PHARMACOLOGY & THERAPEUTICS (2016)
PDE1C deficiency antagonizes pathological cardiac remodeling and dysfunction
Walter E. Knight et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Modulation of Compartmentalised Cyclic Nucleotide Signalling via Local Inhibition of Phosphodiesterase Activity
Marcella Brescia et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
UCR1C is a novel activator of phosphodiesterase 4 (PDE4) long isoforms and attenuates cardiomyocyte hypertrophy
Li Wang et al.
CELLULAR SIGNALLING (2015)
Cardiac Hypertrophy Is Inhibited by a Local Pool of cAMP Regulated by Phosphodiesterase 2
Anna Zoccarato et al.
CIRCULATION RESEARCH (2015)
Regulation of Sarcoplasmic Reticulum Ca2+ ATPase 2 (SERCA2) Activity by Phosphodiesterase 3A (PDE3A) in Human Myocardium PHOSPHORYLATION-DEPENDENT INTERACTION OF PDE3A1 WITH SERCA2
Faiyaz Ahmad et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Phosphodiesterase 10A Is Tethered to a Synaptic Signaling Complex in Striatum
Corina Russwurm et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease
Dong I. Lee et al.
NATURE (2015)
Targeted disruption of PDE3B, but not PDE3A, protects murine heart from ischemia/reperfusion injury
Youn Wook Chung et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
PDE2 activity differs in right and left rat ventricular myocardium and differentially regulates β2 adrenoceptor-mediated effects
Fernando Soler et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2015)
Sildenafil Does Not Prevent Heart Hypertrophy and Fibrosis Induced by Cardiomyocyte Angiotensin II Type 1 Receptor Signaling
Julia Straubinger et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
PDE2-mediated cAMP hydrolysis accelerates cardiac fibroblast to myofibroblast conversion and is antagonized by exogenous activation of cGMP signaling pathways
C. Vettel et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2014)
Dual PDE3/4 and PDE4 Inhibitors: Novel Treatments For COPD and Other Inflammatory Airway Diseases
Katharine H. Abbott-Banner et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2014)
The upstream conserved regions (UCRs) mediate homo- and hetero-oligomerization of type 4 cyclic nucleotide phosphodiesterases (PDE4s)
Moses Xie et al.
BIOCHEMICAL JOURNAL (2014)
Genetic Deletion and Pharmacological Inhibition of Phosphodiesterase 10A Protects Mice From Diet-Induced Obesity and Insulin Resistance
Andrea R. Nawrocki et al.
DIABETES (2014)
Phosphodiesterase 3A1 Protects the Heart Against Angiotensin II-induced Cardiac Remodeling Through Regulation of Transforming Growth Factor-β Expression
Shoji Iwaya et al.
INTERNATIONAL HEART JOURNAL (2014)
Novel Approaches and Opportunities for Cardioprotective Signaling Through 3′,5′-Cyclic Guanosine Monophosphate Manipulation
Justin S. Bice et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2014)
Cyclic AMP synthesis and hydrolysis in the normal and failing heart
Aziz Guellich et al.
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2014)
Roles of cGMP-dependent protein kinase I (cGKI) and PDE5 in the regulation of Ang II-induced cardiac hypertrophy and fibrosis
Enrico Patrucco et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Targeted disruption of the heat shock protein 20-phosphodiesterase 4D (PDE4D) interaction protects against pathological cardiac remodelling in a mouse model of hypertrophy
Tamara P. Martin et al.
FEBS OPEN BIO (2014)
Phosphodiesterase Type 3A Regulates Basal Myocardial Contractility Through Interacting With Sarcoplasmic Reticulum Calcium ATPase Type 2a Signaling Complexes in Mouse Heart
Sanja Beca et al.
CIRCULATION RESEARCH (2013)
Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction A Randomized Clinical Trial
Margaret M. Redfield et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Cyclic nucleotide phosphodiesterase 3A1 protects the heart against ischemia-reperfusion injury
Masayoshi Oikawa et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2013)
Phosphodiesterase-2 Is Up-Regulated in Human Failing Hearts and Blunts β-Adrenergic Responses in Cardiomyocytes
Hind Mehel et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
A Meta-Analysis of Thyroid-Related Traits Reveals Novel Loci and Gender-Specific Differences in the Regulation of Thyroid Function
Eleonora Porcu et al.
PLOS GENETICS (2013)
PDE3 and PDE4 Isozyme-Selective Inhibitors Are Both Required for Synergistic Activation of Brown Adipose Tissues
Stephen M. Kraynik et al.
MOLECULAR PHARMACOLOGY (2013)
Phosphodiesterases and subcellular compartmentalized cAMP signaling in the cardiovascular system
Alessandra Stangherlin et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2012)
PKA phosphorylation of the small heat-shock protein Hsp20 enhances its cardioprotective effects
Helen V. Edwards et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2012)
Chronic Inhibition of cGMP Phosphodiesterase 5A Improves Diabetic Cardiomyopathy A Randomized, Controlled Clinical Trial Using Magnetic Resonance Imaging With Myocardial Tagging
Elisa Giannetta et al.
CIRCULATION (2012)
Nitric oxide synthase and cyclic GMP signaling in cardiac myocytes: From contractility to remodeling
Joanna Hammond et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2012)
Phosphodiesterases coordinate cAMP propagation induced by two stimulatory G protein-coupled receptors in hearts
Shubai Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA/Rho-kinase pathway
Vinh Q. Chau et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2011)
Conserved expression and functions of PDE4 in rodent and human heart
Wito Richter et al.
BASIC RESEARCH IN CARDIOLOGY (2011)
Cyclic nucleotide phosphodiesterase 1A: a key regulator of cardiac fibroblast activation and extracellular matrix remodeling in the heart
Clint L. Miller et al.
BASIC RESEARCH IN CARDIOLOGY (2011)
Phosphodiesterase 4D Regulates Baseline Sarcoplasmic Reticulum Ca2+ Release and Cardiac Contractility, Independently of L-Type Ca2+ Current
Sanja Beca et al.
CIRCULATION RESEARCH (2011)
PDE5 Inhibition With Sildenafil Improves Left Ventricular Diastolic Function, Cardiac Geometry, and Clinical Status in Patients With Stable Systolic Heart Failure Results of a 1-Year, Prospective, Randomized, Placebo-Controlled Study
Marco Guazzi et al.
CIRCULATION-HEART FAILURE (2011)
Novel Trends in the Treatment of Cardiovascular Disorders: Site- and Event- Selective Adenosinergic Drugs
A. J. Szentmiklosi et al.
CURRENT MEDICINAL CHEMISTRY (2011)
Phosphodiesterase 4B in the cardiac L-type Ca2+ channel complex regulates Ca2+ current and protects against ventricular arrhythmias in mice
Jerome Leroy et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Disruption of the cyclic AMP phosphodiesterase-4 (PDE4)-HSP20 complex attenuates the β-agonist induced hypertrophic response in cardiac myocytes
Y. Y. Sin et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2011)
Oxidative Stress Regulates Left Ventricular PDE5 Expression in the Failing Heart
Zhongbing Lu et al.
CIRCULATION (2010)
Phosphodiesterase 8A (PDE8A) regulates excitation-contraction coupling in ventricular myocytes
Enrico Patrucco et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2010)
Interplay of Palmitoylation and Phosphorylation in the Trafficking and Localization of Phosphodiesterase 10A: Implications for the Treatment of Schizophrenia
Erik I. Charych et al.
JOURNAL OF NEUROSCIENCE (2010)
Myocardial Remodeling Is Controlled by Myocyte-Targeted Gene Regulation of Phosphodiesterase Type 5
Manling Zhang et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes
Robert Lukowski et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Ventricular Phosphodiesterase-5 Expression Is Increased in Patients With Advanced Heart Failure and Contributes to Adverse Ventricular Remodeling After Myocardial Infarction in Mice
Peter Pokreisz et al.
CIRCULATION (2009)
Role of Ca2+/Calmodulin-Stimulated Cyclic Nucleotide Phosphodiesterase 1 in Mediating Cardiomyocyte Hypertrophy
Clint L. Miller et al.
CIRCULATION RESEARCH (2009)
Decreased Expression and Activity of cAMP Phosphodiesterases in Cardiac Hypertrophy and Its Impact on β-Adrenergic cAMP Signals
Aniella Abi-Gerges et al.
CIRCULATION RESEARCH (2009)
Immunohistochemical Localization of Phosphodiesterase 2A in Multiple Mammalian Species
Diane T. Stephenson et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2009)
cGMP-Hydrolytic Activity and Its Inhibition by Sildenafil in Normal and Failing Human and Mouse Myocardium
Fabrice Vandeput et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Sildenafil Stops Progressive Chamber, Cellular, and Molecular Remodeling and Improves Calcium Handling and Function in Hearts With Pre-Existing Advanced Hypertrophy Caused by Pressure Overload
Takahiro Nagayama et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes
Manling Zhang et al.
CELLULAR SIGNALLING (2008)
Adenylyl cyclase type 6 deletion decreases left ventricular function via impaired calcium handling
Tong Tang et al.
CIRCULATION (2008)
Mechanisms of disease: detrimental adrenergic signaling in acute decompensated heart failure
David S. Feldman et al.
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE (2008)
Phosphodiesterase type 5 - Expanding roles in cardiovascular regulation
David A. Kass et al.
CIRCULATION RESEARCH (2007)
Cyclic nucleotide phosphodiesterase PDE1C1 in human cardiac myocytes
Fabrice Vandeput et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Disruption of type 5 adenylyl cyclase enhances desensitization of cyclic adenosine monophosphate signal and increases Akt signal with chronic catecholamine stress
Satoshi Okumura et al.
CIRCULATION (2007)
Differential regulation of endothelial cell permeability by cGMP via phosphodiesterases 2 and 3
James Surapisitchat et al.
CIRCULATION RESEARCH (2007)
Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice
Bing Sun et al.
CELLULAR SIGNALLING (2007)
Metabolic mechanisms in heart failure
Houman Ashrafian et al.
CIRCULATION (2007)
Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility
Jayan Nagendran et al.
CIRCULATION (2007)
Adenosinergic cardioprotection: Multiple receptors, multiple pathways
Jason N. Peart et al.
PHARMACOLOGY & THERAPEUTICS (2007)
Compartmentalization of cardiac β-adrenergic inotropy modulation by phosphodiesterase type 5
Eiki Takimoto et al.
CIRCULATION (2007)
cAMP-specific phosphodiesterase-4 enzymes in the cardiovascular system - A molecular toolbox for generating compartmentalized cAMP signaling
Miles D. Houslay et al.
CIRCULATION RESEARCH (2007)
Activation of extracellular signal-regulated kinase 5 reduces cardiac apoptosis and dysfunction via inhibition of a phosphodiesterase 3A/inducible cAMP early repressor feedback loop
Chen Yan et al.
CIRCULATION RESEARCH (2007)
Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial KATP channels when administered at reperfusion following ischemia in rabbits
Fadi N. Salloum et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2007)
Compartmentation of cyclic nucleotide signaling in the heart - The role of cyclic nucleotide phosphodiesterases
Rodolphe Fischmeister et al.
CIRCULATION RESEARCH (2006)
Restricted diffusion of a freely diffusible second messenger: mechanisms underlying compartmentalized cAMP signalling
M. Zaccolo et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2006)
Increased cardiac adenylyl cyclase expression is associated with increased survival after myocardial infarction
Toshiyuki Takahashi et al.
CIRCULATION (2006)
cAMP is a ligand for the tandem GAF domain of human phosphodiesterase 10 and cGMP for the tandem GAF domain of phosphodiesterase 11
M Gross-Langenhoff et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Compartmentalized phosphodiesterase-2 activity blunts β-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway
M Mongillo et al.
CIRCULATION RESEARCH (2006)
Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use
Andrew T. Bender et al.
PHARMACOLOGICAL REVIEWS (2006)
Sildenafil inhibits β-adrenergic-stimulated cardiac contractility in humans
BA Borlaug et al.
CIRCULATION (2005)
A positive feedback loop of phosphodiesterase 3 (PDE3) and inducible cAMP early repressor (ICER) leads to cardiomyocyte apoptosis
B Ding et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias
SE Lehnart et al.
CELL (2005)
The protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways
KL Dodge-Kafka et al.
NATURE (2005)
High lung PDE5: A strong basis for treating pulmonary hypertension with PDE5 inhibitors
JD Corbin et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis - Implication in heart failure
B Ding et al.
CIRCULATION (2005)
Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity
PW Fisher et al.
CIRCULATION (2005)
Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis
A Das et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Functional effects of C-type natriuretic peptide and nitric oxide are attenuated in hypertrophic myocytes from pressure-overloaded mouse hearts
J Su et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2005)
The role of cyclic nucleotide phosphodiesterases in the regulation of adipocyte lipolysis
PB Snyder et al.
JOURNAL OF LIPID RESEARCH (2005)
Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy
E Takimoto et al.
NATURE MEDICINE (2005)
cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism
E Takimoto et al.
CIRCULATION RESEARCH (2005)
What is the role of β-adrenergic signaling in heart failure?
MJ Lohse et al.
CIRCULATION RESEARCH (2003)
Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system
DH Maurice et al.
MOLECULAR PHARMACOLOGY (2003)
Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload
S Okumura et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Identification and distribution of different mRNA variants produced by differential splicing in the human phosphodiesterase 9A gene
C Rentero et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Sildenafil citrate does not affect cardiac contractility in human or dog heart
J Corbin et al.
CURRENT MEDICAL RESEARCH AND OPINION (2003)
Genomic organization, chromosomal localization, and alternative splicing of the human phosphodiesterase 8B gene
M Hayashi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2002)
Enhanced activities and gene expression of phosphodiesterase types 3 and 4 in pressure-induced congestive heart failure
K Takahashi et al.
HEART AND VESSELS (2002)
Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial KATP channels in rabbits
R Ockaili et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2002)
Increased effects of C-type natriuretic peptide on cardiac ventricular contractility and relaxation in guanylyl cyclase A-deficient mice
M Pierkes et al.
CARDIOVASCULAR RESEARCH (2002)
Human phosphodiesterase 8A splice variants: cloning, gene organization, and tissue distribution
P Wang et al.
GENE (2001)
Cardiac phosphodiesterase 5 (cGMP-specific) modulates β-adrenergic signaling in vivo and is down-regulated in heart failure
H Senzaki et al.
FASEB JOURNAL (2001)
Cyclic GMP regulation of the L-type Ca2+ channel current in human atrial myocytes
G Vandecasteele et al.
JOURNAL OF PHYSIOLOGY-LONDON (2001)
mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module
KL Dodge et al.
EMBO JOURNAL (2001)
Remodelling of ionic currents in hypertrophied and failing hearts of transgenic mice overexpressing calsequestrin
BC Knollmann et al.
JOURNAL OF PHYSIOLOGY-LONDON (2000)
Paracrine and autocrine effects of nitric oxide on myocardial function
AM Shah et al.
PHARMACOLOGY & THERAPEUTICS (2000)
Share Paper
